Arcutis Biotherapeutics (ARQT) Debt to Equity (2021 - 2025)
Historic Debt to Equity for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $0.69.
- Arcutis Biotherapeutics' Debt to Equity fell 4745.31% to $0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.69, marking a year-over-year decrease of 4745.31%. This contributed to the annual value of $0.68 for FY2024, which is 7010.1% down from last year.
- According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Debt to Equity is $0.69, which was down 4745.31% from $0.78 recorded in Q2 2025.
- Arcutis Biotherapeutics' 5-year Debt to Equity high stood at $4.3 for Q3 2023, and its period low was $0.24 during Q4 2021.
- Over the past 5 years, Arcutis Biotherapeutics' median Debt to Equity value was $0.84 (recorded in 2024), while the average stood at $1.2.
- Per our database at Business Quant, Arcutis Biotherapeutics' Debt to Equity soared by 56286.67% in 2023 and then crashed by 7010.1% in 2024.
- Arcutis Biotherapeutics' Debt to Equity (Quarter) stood at $0.24 in 2021, then surged by 288.25% to $0.94 in 2022, then surged by 141.19% to $2.28 in 2023, then crashed by 70.1% to $0.68 in 2024, then grew by 0.87% to $0.69 in 2025.
- Its Debt to Equity was $0.69 in Q3 2025, compared to $0.78 in Q2 2025 and $0.75 in Q1 2025.